Vascular and Endovascular Surgery Department, Belfast City Hospital, Lisburn Road, Belfast BT9 7AB, United Kingdom.
Eur J Vasc Endovasc Surg. 2011 Oct;42(4):434-9. doi: 10.1016/j.ejvs.2011.03.022. Epub 2011 Apr 20.
Evidence supports the introduction of an abdominal aortic aneurysm (AAA) screening programme. The aims of this study were to estimate future disease patterns and to determine the effect of the proportion attending on the programme's cost-effectiveness.
The results of the local AAA screening programme were reviewed. Ultrasonic infrarenal aortic diameter of 30 mm was considered aneurysmal. Projected population numbers from the Department of Health and current disease prevalence were used to estimate future number of potential patients. The Multi-centre Aneurysm Screening Study (MASS) Markov model was used to calculate an incremental cost-effectiveness ratio (ICER) and 95% uncertainty intervals (UI), using a 30-year time horizon and 3.5% per annum discount, to determine the effect of attendance.
Men were recruited from August 2004 to May 2010. 13316 were invited for a scan and 5931 (44.5%) attended. 321 AAA were diagnosed, giving a prevalence of 5.4%, while 27 large AAA (0.46%) were repaired. The annual incidence of AAA until 2021 will range from 441 to 526, with an incidence of 40-48 large AAA, with both showing a gradual increase with time. Using this attendance rate, the ICER was calculated at £2350 per life-year gained (95% UI: £1620-£4290), or £3020 per quality-adjusted life-year gained (95% UI: £2080-£5500).
The prevalence of disease in this local AAA screening was similar to other studies. The low attendance will result in many AAA being missed, but will not impact greatly on the long-term cost-effectiveness.
有证据支持引入腹主动脉瘤(AAA)筛查计划。本研究旨在评估未来的疾病模式,并确定参与率对该计划成本效益的影响。
回顾了当地的 AAA 筛查计划的结果。超声下肾下主动脉直径为 30mm 被认为是动脉瘤。利用卫生部的预期人口数量和当前疾病流行率来估计潜在患者的未来数量。使用多中心动脉瘤筛查研究(MASS)Markov 模型来计算增量成本效益比(ICER)和 95%置信区间(UI),使用 30 年时间范围和 3.5%的年度贴现率来确定参与率的影响。
男性于 2004 年 8 月至 2010 年 5 月被招募。共邀请 13316 人进行扫描,5931 人(44.5%)参加。共诊断出 321 个 AAA,患病率为 5.4%,同时有 27 个大 AAA(0.46%)需要修复。到 2021 年,AAA 的年发病率将在 441 到 526 之间波动,发病率为 40-48 个大 AAA,两者都随着时间的推移逐渐增加。使用这种参与率,ICER 计算为每获得一个生命年的成本为 2350 英镑(95%UI:1620-4290 英镑),或每获得一个质量调整生命年的成本为 3020 英镑(95%UI:2080-5500 英镑)。
本研究中当地 AAA 筛查的疾病患病率与其他研究相似。低参与率将导致许多 AAA 被遗漏,但不会对长期成本效益产生重大影响。